London, 03 September 2015: Technavio, the independent tech-focused global research firm, has published a report on the erythropoietin market in Japan 2015-2019, which is expected to grow at a CAGR of 1.16% during 2014-2019.
Japan is considered one of the largest markets for erythropoietin drugs. Pharmaceutical companies form alliances with global leaders to market erythropoietin drugs in Japan. Patent expiries of many originator molecule drugs have increased the interest of pharmaceutical companies to develop their biosimilar versions.
“Advances in technology have led to the development of innovative formulations such as peptide-based and non-peptide-based ESAs and erythropoietin gene therapy drugs,” says Faisal Ghaus, Vice President of Technavio.
“These next-generation formulations may prove to be better for treating anemia than the available therapeutic regimens. Peptide-based ESAs are developed by the genetic fusion of erythropoietin with the Fc region of human immunoglobulin G1 antibody.”
Key Market Drivers
- Increased incidence of anemia
- Reimbursement for erythropoietin preparations
- Favorable growth opportunities
Key Market Trends
- Strategic alliances
- Increased R&D of innovative molecule drugs
- Focus on biosimilars
Key Market Vendors
- Chugai Pharmaceutical
- JCR Pharmaceuticals
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
